Evotec, Roche discontinue EVT 101
Evotec AG (Xetra:EVT) and partner Roche (SIX:ROG; OTCQX:RHHBY) discontinued development of EVT 101 after encountering difficulties in recruiting patients for a Phase II trial for treatment-resistant depression. The partners added that the need to "sharpen" the toxicology profile and the possible need for an altered dose scheme led to delays for the program. Roche, which funded the Phase II trial, would have had an option to license the NMDA receptor NR2B subtype antagonist and a next-generation product after the trial's completion. Evotec, which now retains all rights to EVT 101 and the follow-on EVT 103, said it will enter into partnering discussions for the products. Evotec added that it would not pursue further clinical development without a partner. EVT-103 has completed a Phase I trial. Evotec fell down EUR 0.26 to EUR 2.71 on Wednesday. ...